BioSouth has been awarded “CMO Startup of the Year” at the prestigious Asia Pacific Biologics CMO Excellence Awards (APBCEA) 2024.
CMO, or contract manufacturing organisation, helps pharmaceutical and biotechnology companies manufacture innovative substances at a commercial scale. These can be pharmaceutical products, but also those products that form part of the bioeconomy such as biological control agents for agriculture, environmental remediation, replacements for fossil fuel-based materials, and even alternative proteins for the food industry.
The awards ceremony was held in conjunction with the 3rd Biologics Contract Manufacturing Asia & 8th Cell & Gene Therapy World Asia on the 10th and 11th of September at the Suntec Singapore Convention & Exhibition Centre.
The award was a consequence of voting from over 10,000 professionals in the biologics, cell and gene therapy and vaccine community in the Asia Pacific region.
For BioSouth the award is a validation of the work that has been done by the team over the last two years to build a committed and capable contract manufacturing operation in New Zealand. The company has capacity for both liquid and solid-state microbial fermentation and scale-up services and is already working with a customer base from not just the Asia and Pacific but also North America and Europe.
Receiving the award was BioSouth’s Chief Technical Officer, John Mead, who also spoke at the prestigious event to over 300 delegates from across the biologicals industry on overcoming some of the challenges of scale-up and large-scale production.